Expert Review of Anticancer Therapy最新文献_第7页

An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1). 评估派姆单抗与曲妥珠单抗、含氟嘧啶和含铂化疗治疗表达PD-L1的HER2阳性胃或胃食管交界处腺癌（CPS≥1）。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-02-09 DOI: 10.1080/14737140.2026.2628069

Kyosuke Seguchi, Akihito Kawazoe, Izuma Nakayama, Kohei Shitara

{"title":"An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1).","authors":"Kyosuke Seguchi, Akihito Kawazoe, Izuma Nakayama, Kohei Shitara","doi":"10.1080/14737140.2026.2628069","DOIUrl":"10.1080/14737140.2026.2628069","url":null,"abstract":"Introduction: Despite the introduction of several novel agents, survival for patients with metastatic gastric or gastroesophageal junction adenocarcinoma remains limited. In human epidermal growth factor receptor 2 (HER-2) positive disease, pembrolizumab plus trastuzumab and fluoropyrimidine- and platinum-based chemotherapy has recently demonstrated a survival benefit, particularly in tumors expressing programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥1 in the phase III KEYNOTE-811 trial.Areas covered: This review summarizes the evolution of HER2-directed therapies in gastric cancer and focuses on the efficacy and safety of pembrolizumab in combination with trastuzumab and chemotherapy. We highlight the mechanistic rationale for dual HER2 and PD-1 blockade, pivotal trial evidence, and other novel HER2-directed therapies currently under active clinical evaluation in the first-line setting. A literature search was conducted using PubMed and ClinicalTrials.gov.Expert opinion: Pembrolizumab plus trastuzumab and chemotherapy has established a new first-line standard of care for patients with HER2-positive, PD-L1 CPS ≥1 metastatic gastric or gastroesophageal junction adenocarcinoma. Nonetheless, primary and acquired resistance driven by HER2 heterogeneity, immune evasion, and dynamic molecular evolution remain major challenges. Next-generation HER2-targeted therapies, including bispecific antibodies, novel antibody - drug conjugates, and dual HER2 antibodies will be crucial to further improve outcomes in this population.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1019-1028"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146117852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating liquid biopsies in non-small cell lung cancer diagnosis and management: opportunities and challenges. 整合液体活检在非小细胞肺癌的诊断和管理：机遇与挑战。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-02-15 DOI: 10.1080/14737140.2026.2630026

Jeong Uk Lim, Yuko Oya, Rui Fu, Kenneth Sooi, Yvonne L E Ang, Ross A Soo

{"title":"Integrating liquid biopsies in non-small cell lung cancer diagnosis and management: opportunities and challenges.","authors":"Jeong Uk Lim, Yuko Oya, Rui Fu, Kenneth Sooi, Yvonne L E Ang, Ross A Soo","doi":"10.1080/14737140.2026.2630026","DOIUrl":"10.1080/14737140.2026.2630026","url":null,"abstract":"Introduction: Liquid biopsy has emerged as an important approach to capture tumor-derived material from blood and other body fluids, offering a minimally invasive window into cancer biology. In non - small cell lung cancer (NSCLC), it enables comprehensive molecular profiling that informs patient management, from guiding therapy choices to monitoring disease status and assessing minimal residual disease (MRD).Areas covered: Its main advantages over tissue biopsy lie in being noninvasive, capable of reflecting tumor heterogeneity and real-time biological changes. These strengths allow liquid biopsy to be applied at different clinical timepoints, including diagnosis, treatment decision-making, evaluation during therapy, detection of resistance, and surveillance for recurrence. Although circulating tumor DNA (ctDNA) remains the most established analyte, the scope is broadening to include circulating RNAs, circulating tumor cells, exosomes, DNA methylation signatures, and tumor-educated platelets, each providing complementary insights. A literature search of PubMed, EMBASE, and Web of Science was conducted without restrictions, supplemented by screening reference lists and major oncology conference abstracts.Expert opinion: While significant progress has been made integrating liquid biopsies in NSCLC, challenges persist, encompassing issues of standardization, cost, and clinical integration.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1029-1040"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia. 哥伦比亚NSCLC围手术期和局部晚期管理的全国德尔菲共识。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-08-01 Epub Date: 2026-04-09 DOI: 10.1080/14737140.2026.2653635

Ricardo Bruges Maya, Milton Lombana, Carlos Andres Carvajal-Fierro, Ricardo Zapata Gonzalez, Juan Jose Ortiz Martinez, Alejandro Gonzalez-Motta, Lina Maria Loaiz Salazar

{"title":"National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia.","authors":"Ricardo Bruges Maya, Milton Lombana, Carlos Andres Carvajal-Fierro, Ricardo Zapata Gonzalez, Juan Jose Ortiz Martinez, Alejandro Gonzalez-Motta, Lina Maria Loaiz Salazar","doi":"10.1080/14737140.2026.2653635","DOIUrl":"10.1080/14737140.2026.2653635","url":null,"abstract":"Objectives: To develop Colombian, evidence-informed consensus recommendations for perioperative systemic therapy and unresectable stage III non-small cell lung cancer (NSCLC), considering local testing and access constraints.Methods: Three Colombian professional societies conducted a modified Delphi process. A multidisciplinary panel completed two anonymous rating rounds in September 2024 and a structured debate. A systematic literature search (2010-2024) informed 34 draft statements spanning diagnostic workup, neoadjuvant and adjuvant therapy, and unresectable stage III management.Results: Consensus was reached for 33/34 statements (97.1%). The panel endorsed multidisciplinary tumor board review and pretreatment molecular profiling. For resectable stage II-III disease without sensitizing EGFR/ALK alterations, neoadjuvant chemo-immunotherapy was preferred. For unresectable stage III, chemoradiotherapy followed by durvalumab consolidation was endorsed for PD-L1-positive tumors; use in PD-L1 tumor proportion score < 1% should be individualized. In EGFR-mutated unresectable stage III disease, durvalumab was not endorsed; osimertinib consolidation was favored. The only non-consensus item was adjuvant atezolizumab for PD-L1 ≥1% after platinum chemotherapy in EGFR/ALK-negative stage II-IIIA disease (AJCC 7th), lacking INVIMA approval at the time.Conclusion: This Delphi consensus provides a practical national framework for perioperative and unresectable stage III NSCLC management in Colombia.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1061-1069"},"PeriodicalIF":3.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming therapeutic resistance in biliary tract cancer: from resistance mechanisms to dynamic precision oncology - a narrative review. 克服胆道肿瘤的治疗耐药：从耐药机制到动态精确肿瘤学的叙述综述。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-28 DOI: 10.1080/14737140.2026.2708771

Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura

{"title":"Overcoming therapeutic resistance in biliary tract cancer: from resistance mechanisms to dynamic precision oncology - a narrative review.","authors":"Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura","doi":"10.1080/14737140.2026.2708771","DOIUrl":"10.1080/14737140.2026.2708771","url":null,"abstract":"Introduction: Biliary tract cancer (BTC) is a biologically heterogeneous and highly aggressive malignancy with limited therapeutic options and poor survival. Although chemotherapy, targeted therapies, and immune checkpoint inhibitors have improved treatment outcomes, intrinsic and acquired resistance remain the major barriers to durable clinical benefit.Areas covered: A comprehensive literature search of PubMed, Embase, and Web of Science was conducted for studies published through June 2026. This narrative review summarizes current mechanisms of therapeutic resistance in BTC, including genetic evolution, clonal selection, epigenetic plasticity, cancer stem cells, non-genetic adaptive resistance, metabolic reprogramming, and tumor microenvironment-mediated immune evasion. Emerging strategies to overcome resistance are discussed, including rational combination therapies based on acquired vulnerability, next-generation targeted therapies, tumor microenvironment remodeling, immunotherapy optimization, epigenetic and metabolic interventions, and precision oncology supported by liquid biopsy and dynamic molecular monitoring.Expert opinion: BTC management is evolving toward biologically informed precision oncology. Integrating comprehensive molecular profiling, longitudinal liquid biopsy, biomarker-guided patient selection, and mechanism-based combination therapies will enable dynamic treatment adaptation and may improve long-term outcomes. Advances in multi-omics, artificial intelligence, and biomarker-driven clinical trial designs are expected to further accelerate personalized therapeutic strategies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":3.0,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The transcriptional landscape in thyroid cancer: current status of circulating biomarkers and liquid biopsy approaches. 甲状腺癌的转录景观：循环生物标志物和液体活检方法的现状。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-28 DOI: 10.1080/14737140.2026.2708770

Srabonti Ghosh, Avik Chakraborty, Bhakti Basu, Sandip Basu

{"title":"The transcriptional landscape in thyroid cancer: current status of circulating biomarkers and liquid biopsy approaches.","authors":"Srabonti Ghosh, Avik Chakraborty, Bhakti Basu, Sandip Basu","doi":"10.1080/14737140.2026.2708770","DOIUrl":"10.1080/14737140.2026.2708770","url":null,"abstract":"Introduction: Thyroid cancer is the most common endocrine malignancy, and despite advances in understanding its genomic drivers, significant challenges remain in predicting tumor behavior, therapeutic response, and disease progression. This review summarizes advances in transcriptomic profiling and liquid biopsy approaches that are reshaping molecular classification, biomarker discovery, and precision management of thyroid cancer.Areas covered: This review examines recent advances in tissue- and liquid biopsy-based transcriptomic approaches for thyroid cancer, including bulk RNA sequencing, single-cell and spatial transcriptomics, extracellular vesicle RNAs, circulating tumor cells, and circulating non-coding RNAs, together with their applications in molecular classification, biomarker discovery, tumor heterogeneity, disease monitoring, therapeutic stratification, and precision oncology. The review also discusses emerging multi-omics integration and challenges in clinical translation. Literature was identified through systematic searches of PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, supplemented by TCGA, GEO, and ClinicalTrials.gov, covering publications from January 2000 to June 2026.Expert opinion: Transcriptomic profiling is poised to redefine thyroid cancer management by moving beyond static morphologic classification toward biologically informed precision medicine through improved molecular classification, risk stratification, therapeutic selection, and longitudinal disease monitoring. However, routine clinical implementation will require standardized methodologies, prospective multicentre validation, and integration with liquid biopsy, multi-omics, and artificial intelligence-driven analytical frameworks.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148577306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19-9 undergoing pancreatic ductal adenocarcinoma resection. 术前Ca 19-9升高患者行胰管腺癌切除术后新辅助化疗与预后的关系

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-27 DOI: 10.1080/14737140.2026.2699780

Ewa Grudzińska, Magdalena Gajda, Sławomir Mrowiec

{"title":"Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19-9 undergoing pancreatic ductal adenocarcinoma resection.","authors":"Ewa Grudzińska, Magdalena Gajda, Sławomir Mrowiec","doi":"10.1080/14737140.2026.2699780","DOIUrl":"10.1080/14737140.2026.2699780","url":null,"abstract":"Background: Serum Ca 19-9 is the most widely used biomarker in pancreatic ductal adenocarcinoma (PDAC). This study assessed the link between preoperative Ca 19-9, neoadjuvant chemotherapy (ChTNeo), and outcomes after pancreatic resection.Research design and methods: We retrospectively analyzed 378 patients with PDAC who underwent resection. Patients were grouped by preoperative Ca 19-9: elevated (>37 U/mL; N = 320) or normal (≤37 U/mL; N = 58). ChTNeo was administered to 99 patients (30.9%) in the elevated group and 35 (60.3%) in the normal group.Results: Local recurrence, distant metastases, and mortality were significantly more frequent in patients with elevated Ca 19-9, while progression-free and overall survival were shorter. Patients with normal Ca 19-9 had excellent outcomes regardless of ChTNeo. Patients with elevated preoperative Ca 19-9 and ChTNeo administration had significantly better outcomes than those undergoing upfront surgery.Conclusions: Normal preoperative Ca 19-9 identifies a group with a favorable prognosis after PDAC resection. Elevated preoperative Ca 19-9 is associated with worse oncological outcomes. Among these patients, ChTNeo was associated with better treatment outcomes than upfront surgery; however, because baseline Ca 19-9 levels before ChTNeo were unavailable, these findings should not be interpreted as evidence that elevated baseline Ca 19-9 predicts benefit from neoadjuvant chemotherapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing the therapeutic plateau in higher-risk myelodysplastic syndromes: rethinking trial design strategies. 解决高危骨髓增生异常综合征的治疗平台期：重新思考试验设计策略。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-27 DOI: 10.1080/14737140.2026.2710392

Pasquale Niscola, Maria Ilaria Del Principe, Fabio Efficace

引用次数: 0

Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection. 胰腺癌门静脉切除术：从技术可行性到生物学患者选择。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-24 DOI: 10.1080/14737140.2026.2709779

Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura

{"title":"Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection.","authors":"Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura","doi":"10.1080/14737140.2026.2709779","DOIUrl":"10.1080/14737140.2026.2709779","url":null,"abstract":"Introduction: Portal vein resection (PVR) has become an established component of pancreatic cancer surgery for selected patients with portal vein-superior mesenteric vein involvement. Although advances in surgical techniques and multidisciplinary treatment have improved perioperative outcomes, whether PVR itself independently improves long-term survival remains controversial.Areas covered: This review summarizes the historical evolution of PVR, critically evaluates contemporary evidence regarding its safety and oncological outcomes, and examines the methodological limitations that prevent definitive conclusions regarding its independent survival benefit. We further discuss pathological venous invasion as a marker of aggressive tumor biology and review the emerging concept of biological resectability, incorporating neoadjuvant treatment response, serum CA19-9 dynamics, circulating tumor DNA, molecular profiling, and artificial intelligence into patient selection for surgery.Expert opinion: The value of PVR should no longer be judged solely by technical feasibility or anatomical resectability. Instead, portal vein invasion should be interpreted as both an anatomical and biological finding, and indications for PVR should be guided by integrated biological assessment within a multidisciplinary treatment strategy. Future progress will depend on identifying patients most likely to derive meaningful oncological benefit through biologically informed precision surgical oncology.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. 评价利替尼单抗与卡铂和紫杉醇联合治疗肛管鳞状细胞癌的疗效。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-24 DOI: 10.1080/14737140.2026.2708761

Tiffany Foo, Tharani Krishnan, Niall Tebbutt, Timothy Price, Christos Karapetis, Amitesh Roy

{"title":"An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal.","authors":"Tiffany Foo, Tharani Krishnan, Niall Tebbutt, Timothy Price, Christos Karapetis, Amitesh Roy","doi":"10.1080/14737140.2026.2708761","DOIUrl":"10.1080/14737140.2026.2708761","url":null,"abstract":"Introduction: Anal squamous cell carcinoma (SCC) is a rare cancer. Metastatic anal SCC is still a significant clinical challenge due to limited treatment options and poor outcomes.Areas covered: This review paper will focus on retifanlimab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) pathway, and its role in the treatment of metastatic anal SCC, both as monotherapy or in combination with chemotherapy. This review will evaluate its efficacy, safety, and place within the current therapeutic landscape.Expert opinion: The POD1UM-303 trial is the first randomized phase III study for patients with metastatic and locally, advanced unresectable anal SCC. The results from POD1UM-303 are practice-changing, establishing retifanlimab in combination with carboplatin and paclitaxel as a new standard of care for first-line treatment in this setting. Current research includes investigating earlier integration of PD-(L)1 inhibitors with definitive chemoradiotherapy in the locally advanced setting. Further biomarker-driven studies are essential to guide treatment and improve patient selection.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":3.0,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors in people living with HIV and cancer: a Kaplan-Meier-derived individual patient data meta-analysis. 免疫检查点抑制剂在艾滋病和癌症患者中的应用：kaplan -meier衍生的个体患者数据荟萃分析

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-17 DOI: 10.1080/14737140.2026.2702452

Francisco Cezar Aquino de Moraes, Luis Henrique Rios Moreira Rego, Felipe Alves de Paiva, Gustavo Tadeu Freitas Uchôa Matheus, Rommel Mario Rodríguez Burbano, Mario Hiroyuki Hirata

{"title":"Immune checkpoint inhibitors in people living with HIV and cancer: a Kaplan-Meier-derived individual patient data meta-analysis.","authors":"Francisco Cezar Aquino de Moraes, Luis Henrique Rios Moreira Rego, Felipe Alves de Paiva, Gustavo Tadeu Freitas Uchôa Matheus, Rommel Mario Rodríguez Burbano, Mario Hiroyuki Hirata","doi":"10.1080/14737140.2026.2702452","DOIUrl":"10.1080/14737140.2026.2702452","url":null,"abstract":"Introduction: Antiretroviral therapy has enabled people living with HIV (PLWH) to achieve near-normal life expectancy, but non-AIDS-defining cancers are increasingly frequent. Immune checkpoint inhibitors (ICIs) may be effective in this population, although evidence remains limited because PLWH have often been excluded from trials. This study assessed the efficacy and safety of ICIs in PLWH.Methods: We conducted a systematic review and meta-analysis using Medline, Scopus, Web of Science, and Cochrane Library. Studies reporting outcomes of PLWH with malignancies treated with ICIs were included. Analyses were performed in R version 4.4.2.Results: Fourteen studies including 935 patients were analyzed. Compared with people living without HIV, PLWH showed no significant differences in overall survival (HR, 0.88; 95% CI, 0.71-1.08; p = 0.23), progression-free survival (HR, 1.13; 95% CI, 0.89-1.42; p = 0.38), any adverse events (OR, 0.90; 95% CI, 0.52-1.58; p = 0.71), or severe adverse events (OR, 1.04; 95% CI, 0.51-2.10; p = 0.91). In PLWH, the pooled objective response rate was 36%, and disease control rate was 64%.Conclusions: ICIs showed comparable efficacy and safety in PLWH and people living without HIV.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251113906.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0